Targeting the non-canonical roles of PCNA modifies and increases the response to targeted anti-cancer therapy

Receptor tyrosine kinases (RTKs), such as HER2 and/or EGFR are important therapeutic targets in multiple cancer cells. Low and/or short response to targeted therapies are often due to activation of compensatory signaling pathways, and therefore a combination of kinase inhibitors with other anti-canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Søgaard, Caroline K., Nepal, Anala, Petrovic, Voin, Sharma, Animesh, Liabakk, Nina-Beate, Steigedal, Tonje S., Otterlei, Marit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944453/
https://www.ncbi.nlm.nih.gov/pubmed/31921382
http://dx.doi.org/10.18632/oncotarget.27267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944453/
https://www.ncbi.nlm.nih.gov/pubmed/31921382
http://dx.doi.org/10.18632/oncotarget.27267

Ejemplares similares